As everyone is beginning to learn making reliable accurate glucose sensors isn’t easy, making millions of them is even harder. This is the reason Abbott is investing billions to expand Libre capacity. Dexcom already has a swanky new facility in Mesa but likely will add more capacity to meet their growing demand. Medtronic on the other hand relies on a series of companies when it comes to making their sensors, one of which is called IntriCon, in fact Medtronic is IntriCon’s largest customer.
Today IntriCon lowered revenue guidance stating;
“IntriCon updated its full year 2019 revenue guidance to . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.